Brands & Strategies: Type 2 Diabetes

Table of Contents

Executive Summary

Section 1: Introduction

• Report Scope
• Survey Methodology

Section 2: Disease Dynamics

• Type 2 Diabetes Background
• Prevalence and Diagnosis
  • Major Markets Statistics and Key Findings
  • US Statistics and Key Findings
  • Europe Statistics and Key Findings
  • Japan Statistics and Key Findings
• Prescribers
  • General Prescriber Trends
  • Key Drivers of Prescriber Decisions
• Reimbursement Issues
  • US
  • Europe
  • Japan
• Treatment Dynamics
  • Existing Therapies
  • Emerging Therapies

Section 3: Competitive Analysis

• Overview of Competitive Landscape
• Brand Overview
• Promotional Spending
• Physician Perceptions
  • Perceptions of Competitors in Type 2 Diabetes
  • Perceptions of Brands in Type 2 Diabetes

Section 4: Established Competitors

Takeda

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
  • Current Positioning
  • Market Strategy
  • Outlook
• Actos
  • Current Positioning
  • Actos Competitive Analysis
  • Key Brand Strategies
  • Future Positioning
• Glufast
  • Current Positioning
  • Future Positioning
• Emerging: alogliptin
  • Current Positioning
  • Future Positioning

GlaxoSmithKline

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
  • Current Positioning
  • Market Strategy
  • Outlook
• Avandia
  • Current Positioning
  • Avandia Competitive Analysis
  • Key Brand Strategies
  • Future Positioning
• Emerging: sergliflozin and 189075
  • Current Positioning
  • Future Positioning

Novo Nordisk

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
  • Current Positioning
  • Market Strategy
  • Outlook
• Prandin
  • Current Positioning
  • Prandin Competitive Analysis
  • Future Positioning
• Emerging: liraglutide
  • Current Positioning
  • Future Positioning

Eli Lilly

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
  • Current Positioning
  • Market Strategy
  • Outlook
• Byetta
  • Current Positioning
  • Byetta Competitive Analysis
  • Key Brand Strategies
  • Future Positioning

Amylin

• Strategic Overview
  • Diabetes Product Portfolio
  • Current Positioning and Outlook
• Symlin
  • Current Positioning
  • Future Positioning

Bristol-Myers Squibb

• Strategic Overview
  • Diabetes Product Portfolio
  • Current Positioning and Outlook
• Emerging: saxagliptin
  • Current Positioning
  • Future Positioning
• Emerging: dapagliflozin
  • Current Positioning
  • Future Positioning

Sanofi-Aventis

• Strategic Overview
  • Diabetes Product Portfolio
  • Current Positioning and Outlook
• Emerging: AVE-0010
  • Current and Future Positioning
• Emerging: AVE-2268
  • Current and Future Positioning

Section 5: Emerging Competitors

Novartis

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
  • Current Positioning
  • Market Strategy
  • Outlook
• Starlix
  • Current Positioning
  • Starlix Competitive Analysis
  • Future Positioning
• Emerging: Galvus
  • Current Positioning
  • Galvus Competitive Analysis
  • Future Positioning

Merck

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
  • Current Positioning
  • Outlook
• Januvia
  • Current Positioning
  • Januvia Competitive Analysis
  • Key Brand Strategies
  • Future Positioning

Metabolex

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
• Emerging: metaglidasen
  • Current Positioning
  • Future Positioning

Daiichi-Sankyo

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
• Emerging: rivoglitazone
  • Current Positioning
  • Future Positioning

Boehringer Ingelheim

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
• Emerging: BI-1356
  • Current Positioning
  • Future Positioning

Roche

• Strategic Overview
  • Diabetes Product Portfolio
  • Goals and Vision in Diabetes
• Emerging: BIM-51077
  • Current Positioning
  • Future Positioning

Section 6: Market Forecast

• Market Overview
  • Drug Sales by Region
  • Drug Sales by Class
• Type 2 Diabetes Market Forecast
  • PPAR Agonists
  • DPP-IV Inhibitors
  • GLP-1 Analogues
  • Meglitinides
  • Amylin Analogues
  • SGLT Inhibitors

Section 7: Appendix

• Acronyms and Abbreviations
• Methodology
  • Epidemiology
  • Market Forecast
  • Emerging Therapy Prices
  • Competitive Analysis Methodology

Table of Exhibits

Executive Summary

• Exhibit 1: Key Parameters of the Type 2 Diabetes Market
• Exhibit 2: Type 2 Diabetes Treatment Market ($US), Major Markets, 2006-2011
• Exhibit 3: Type 2 Diabetes Market Competitive Landscape, 2006 and 2011
• Exhibit 4: Leading Brands in the Type 2 Diabetes Market, 2006 and 2011
• Exhibit 5: Physician Ranked "Best" Type 2 Diabetes Market Competitors

Section 1: Introduction

• Exhibit 6: Surveyed Physicians' Years of Practice
• Exhibit 7: Surveyed Physicians' Patients per Month
• Exhibit 8: Surveyed Physicians' Geographic Distribution

Section 2: Disease Dynamics

• Exhibit 9: Clinical Progression of Type 2 Diabetes
• Exhibit 10: Existing Type 2 Diabetes Drugs, by Drug Class
• Exhibit 11: Prevalent and Diagnosed Type 2 Diabetes Cases, Major Markets
• Exhibit 12: Prevalent and Diagnosed Type 2 Diabetes Cases, US
• Exhibit 13: Prevalent and Diagnosed Type 2 Diabetes Cases, Europe
• Exhibit 14: Prevalent and Diagnosed Type 2 Diabetes Cases, Europe, Continued
• Exhibit 15: Prevalent and Diagnosed Type 2 Diabetes Cases, Japan
• Exhibit 16: Preferred Information Sources for Type 2 Diabetes Physicians
• Exhibit 17: Non-Clinical Factors that Influence Physicians' Drug Choice in Type 2 Diabetes
• Exhibit 18: US Formulary Status of PPAR Agonists
• Exhibit 19: US Formulary Status of Other Type 2 Diabetes Treatments
• Exhibit 20: Treatment Algorithm for Type 2 Diabetes
• Exhibit 21: Emerging Type 2 Diabetes Drugs, by Drug Class

Section 3: Competitive Analysis

• Exhibit 22: Leading Brands in the Type 2 Diabetes Market, 2006 and 2011
• Exhibit 23: Type 2 Diabetes Market Competitive Position, 2006 and 2011
• Exhibit 24: Type 2 Diabetes Market ($US), Branded Sales by Company, 2006-2011
• Exhibit 25: Label Comparisons for Leading Brands in Type 2 Diabetes, To-Date
• Exhibit 26: Price per Treated Day of Leading Brands in Type 2 Diabetes ($US), 2006
• Exhibit 27: Promotional Spend for Type 2 Diabetes Therapies, by Company, 2006
• Exhibit 28: Promotional Spend for Type 2 Diabetes Therapies, by Brand, 2006
• Exhibit 29: Physician Perception of the Most Influential Companies in Type 2 Diabetes
• Exhibit 30: Physician Ranked "Best" Type 2 Diabetes Market Competitors
• Exhibit 31: Top-of-Mind Brands Type 2 Diabetes Treatment

Section 4: Established Competitors

• Exhibit 32: Summary of Takeda' s Diabetes Product Portfolio
• Exhibit 33: Takeda' s Influence in Type 2 Diabetes
• Exhibit 34: Physician Perceptions of Takeda in Type 2 Diabetes
• Exhibit 35: Physician Preferences for Actos
• Exhibit 36: Physician Perceptions of Actos
• Exhibit 37: Ongoing Clinical Trials for Actos in Diabetes
• Exhibit 38: Ongoing Clinical Trials for Actos in Other Indications
• Exhibit 39: Actos Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 40: Actos Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 41: Actos Franchise Revenue ($US), by Country, 2006-2011
• Exhibit 42: Glufast Revenue ($US), by Country, 2006-2011
• Exhibit 43: Expected Alogliptin Revenue ($US), by Region, 2006-2011
• Exhibit 44: Expected Alogliptin Revenue ($US), by Country, 2006-2011
• Exhibit 45: Alogliptin' s Expected Price to Treat per Day
• Exhibit 46: Summary of GSK' s Diabetes Product Portfolio
• Exhibit 47: GSK' s Influence in Type 2 Diabetes
• Exhibit 48: Physician Perceptions of GSK in Type 2 Diabetes
• Exhibit 49: Physician Perceptions of Avandia
• Exhibit 50: Physician Concern of Associated Avandia Risks
• Exhibit 51: Ongoing Clinical Trials for Avandia
• Exhibit 52: Ongoing Clinical Trials for Avandia, Continued
• Exhibit 53: Clinical Trials for Avandia in Alzheimer' s Disease
• Exhibit 54: Avandia Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 55: Avandia Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 56: Avandia Franchise Revenue ($US), by Country, 2006-2011
• Exhibit 57: Expected Sergliflozin and 189075 Revenue ($US), by Country, 2010-2011
• Exhibit 58: Summary of Novo Nordisk' s Diabetes Product Portfolio
• Exhibit 59: Novo Nordisk' s Influence in Type 2 Diabetes
• Exhibit 60: Physician Perceptions of Novo Nordisk in Type 2 Diabetes
• Exhibit 61: Physician Perceptions of Prandin
• Exhibit 62: Prandin Revenue ($US), by Region, 2006-2011
• Exhibit 63: Prandin Revenue ($US), by Country, 2006-2011
• Exhibit 64: Expected Liraglutide Revenue ($US), by Region, 2006-2011
• Exhibit 65: Expected Liraglutide Revenue ($US), by Country, 2006-2011
• Exhibit 66: Liraglutide' s Expected Price to Treat per Day
• Exhibit 67: Summary of Eli Lilly' s Diabetes Product Portfolio
• Exhibit 68: Eli Lilly' s Influence in Type 2 Diabetes
• Exhibit 69: Physician Perceptions of Eli Lilly in Type 2 Diabetes
• Exhibit 70: Physician Perceptions of Byetta
• Exhibit 71: Ongoing Clinical Trials for Byetta
• Exhibit 72: Ongoing Clinical Trials for Byetta, Continued
• Exhibit 73: Ongoing Clinical Trials for Byetta in Obesity
• Exhibit 74: Byetta Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 75: Byetta Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 76: Byetta Franchise Revenue ($US), by Country, 2006-2011
• Exhibit 77: Summary of Amylin' s Diabetes Product Portfolio
• Exhibit 78: Amylin' s Influence in Type 2 Diabetes
• Exhibit 79: Physician Reasons for Not Prescribing Symlin
• Exhibit 80: Symlin Revenue ($US), by Region, 2006-2011
• Exhibit 81: Symlin Revenue ($US), by Country, 2006-2011
• Exhibit 82: Summary of BMS' Diabetes Product Portfolio
• Exhibit 83: Saxagliptin Revenue ($US), by Region, 2006-2011
• Exhibit 84: Saxagliptin Revenue ($US), by Country, 2006-2011
• Exhibit 85: Saxagliptin' s Expected Price to Treat per Day
• Exhibit 86: Expected Dapagliflozin Revenue ($US), by Country, 2006-2011
• Exhibit 87: Dapagliflozin' s Expected Price to Treat per Day
• Exhibit 88: Summary of Sanofi-Aventis' Diabetes Product Portfolio
• Exhibit 89: Expected AVE-0010 Revenue ($US), by Country, 2011
• Exhibit 90: Expected AVE-2268 Revenue ($US), by Country, 2011

Section 5: Emerging Competitors

• Exhibit 91: Summary of Novartis' Diabetes Product Portfolio
• Exhibit 92: Novartis' Influence in Type 2 Diabetes
• Exhibit 93: Physician Perceptions of Starlix
• Exhibit 94: Starlix Revenue ($US), by Region, 2006-2011
• Exhibit 95: Starlix Revenue ($US), by Country, 2006-2011
• Exhibit 96: Physicians' Enthusiasm for Galvus
• Exhibit 97: Expected Galvus Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 98: Expected Galvus Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 99: Expected Galvus Franchise Revenue ($US), by Country, 2006-2011
• Exhibit 100: Galvus' Expected Price to Treat per Day
• Exhibit 101: Summary of Merck' s Diabetes Product Portfolio
• Exhibit 102: Merck' s Influence in Type 2 Diabetes
• Exhibit 103: Physician Perceptions of Merck in Type 2 Diabetes
• Exhibit 104: Physician Perceptions of Januvia
• Exhibit 105: Physicians' Increasing Use of Januvia
• Exhibit 106: Ongoing Clinical Trials for Januvia
• Exhibit 107: Ongoing Clinical Trials for Januvia, Continued
• Exhibit 108: Januvia Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 109: Januvia Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 110: Januvia Franchise Revenue ($US), by Country, 2006-2011
• Exhibit 111: Summary of Metabolex' Diabetes Product Portfolio
• Exhibit 112: Expected Metaglidasen Revenue ($US), by Region, 2006-2011
• Exhibit 113: Expected Metaglidasen Revenue ($US), by Country, 2006-2011
• Exhibit 114: Metaglidasen' s Expected Price to Treat per Day
• Exhibit 115: Summary of Daiichi-Sankyo' s Diabetes Product Portfolio
• Exhibit 116: Rivoglitazone Revenue ($US), by Region, 2006-2011
• Exhibit 117: Rivoglitazone Revenue ($US), by Country, 2006-2011
• Exhibit 118: Rivoglitazone' s Expected Price to Treat per Day
• Exhibit 119: Summary of Boehringer Ingelheim' s Diabetes Product Portfolio
• Exhibit 120: Expected BI-1356 Revenue ($US), by Country, 2011
• Exhibit 121: Summary of Roche' s Diabetes Product Portfolio
• Exhibit 122: Expected BIM-51077 Revenue ($US), by Country, 2011

Section 6: Market Forecast

• Exhibit 123: Type 2 Diabetes Market ($US), Major Markets, 2006-2011 (Tabular Format)
• Exhibit 124: Type 2 Diabetes Market ($US), Major Markets, 2006-2011 (Graphical Format)
• Exhibit 125: Timeline of Key Events, Type 2 Diabetes Market, 2006-2011
• Exhibit 126: Type 2 Diabetes Market ($US), by Country, 2006-2011
• Exhibit 127: Type 2 Diabetes Market ($US), by Drug Class, 2006-2011
• Exhibit 128: Type 2 Diabetes Market, by Drug Class, as a % of Total, 2006 and 2011
• Exhibit 129: PPAR Agonist Market ($US), by Drug, 2006-2011
• Exhibit 130: PPAR Agonist Market ($US), by Country, 2006-2011
• Exhibit 131: DPP-IV Inhibitor Market ($US), by Drug, 2006-2011
• Exhibit 132: DPP-IV Inhibitor Market ($US), by Country, 2006-2011
• Exhibit 133: GLP-1 Analogue Market ($US), by Drug, 2006-2011
• Exhibit 134: GLP-1 Analogue Market ($US), by Country, 2006-2011
• Exhibit 135: Meglitinide Market ($US), by Drug, 2006-2011
• Exhibit 136: Meglitinide Market ($US), by Country, 2006-2011
• Exhibit 137: SGLT Inhibitor Market ($US), by Drug, 2006-2011

Section 7: Appendix

• Exhibit 138: Discount Prices